OBI Pharma, Inc. (TPEX:4174)

OBI Pharma Statistics

Total Valuation

OBI Pharma has a market cap or net worth of TWD 6.55 billion. The enterprise value is 6.04 billion.

Market Cap	6.55B
Enterprise Value	6.04B

Important Dates

The next estimated earnings date is Tuesday, November 11, 2025.

Earnings Date	Nov 11, 2025
Ex-Dividend Date	n/a

Share Statistics

OBI Pharma has 262.97 million shares outstanding. The number of shares has increased by 9.28% in one year.

Current Share Class	262.97M
Shares Outstanding	262.97M
Shares Change (YoY)	+9.28%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	6.45%
Owned by Institutions (%)	3.91%
Float	176.10M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	106.05
PB Ratio	1.84
P/TBV Ratio	2.53
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-2.50
EV / Sales	97.83
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.97

Financial Position

The company has a current ratio of 6.54, with a Debt / Equity ratio of 0.15.

Current Ratio	6.54
Quick Ratio	5.69
Debt / Equity	0.15
Debt / EBITDA	n/a
Debt / FCF	-0.26
Interest Coverage	-197.09

Financial Efficiency

Return on equity (ROE) is -68.89% and return on invested capital (ROIC) is -35.80%.

Return on Equity (ROE)	-68.89%
Return on Assets (ROA)	-34.62%
Return on Invested Capital (ROIC)	-35.80%
Return on Capital Employed (ROCE)	-61.66%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.01
Inventory Turnover	4.45

Taxes

Income Tax	-2.07M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -62.16% in the last 52 weeks. The beta is 0.40, so OBI Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.40
52-Week Price Change	-62.16%
50-Day Moving Average	27.25
200-Day Moving Average	40.21
Relative Strength Index (RSI)	37.75
Average Volume (20 Days)	1,173,276

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, OBI Pharma had revenue of TWD 61.74 million and -2.41 billion in losses. Loss per share was -9.63.

Revenue	61.74M
Gross Profit	-75.60M
Operating Income	-2.45B
Pretax Income	-2.59B
Net Income	-2.41B
EBITDA	-2.28B
EBIT	-2.45B
Loss Per Share	-9.63

Balance Sheet

The company has 1.96 billion in cash and 533.27 million in debt, giving a net cash position of 1.43 billion or 5.44 per share.

Cash & Cash Equivalents	1.96B
Total Debt	533.27M
Net Cash	1.43B
Net Cash Per Share	5.44
Equity (Book Value)	3.56B
Book Value Per Share	10.04
Working Capital	1.93B

Cash Flow

In the last 12 months, operating cash flow was -1.98 billion and capital expenditures -60.59 million, giving a free cash flow of -2.04 billion.

Operating Cash Flow	-1.98B
Capital Expenditures	-60.59M
Free Cash Flow	-2.04B
FCF Per Share	-7.74

Margins

Gross Margin	-122.43%
Operating Margin	-3,969.36%
Pretax Margin	-4,198.58%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

OBI Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-9.28%
Shareholder Yield	-9.28%
Earnings Yield	-36.84%
FCF Yield	-31.09%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

OBI Pharma has an Altman Z-Score of 7.05 and a Piotroski F-Score of 3.

Altman Z-Score	7.05
Piotroski F-Score	3